Rat Anti-Mouse CD276
- Known as:
- Rat Antibody toMouse CD276
- Catalog number:
- 129-10137
- Product Quantity:
- 250
- Category:
- -
- Supplier:
- Ray Biotech
- Gene target:
- Rat Anti-Mouse CD276
Related genes to: Rat Anti-Mouse CD276
- Gene:
- CD276 NIH gene
- Name:
- CD276 molecule
- Previous symbol:
- -
- Synonyms:
- B7-H3, B7H3, B7RP-2
- Chromosome:
- 15q24.1
- Locus Type:
- gene with protein product
- Date approved:
- 2005-03-04
- Date modifiied:
- 2016-10-05
Related products to: Rat Anti-Mouse CD276
Related articles to: Rat Anti-Mouse CD276
- Mechanical stimulation is a key biomechanical characteristic of the tumor microenvironment and is involved in tumor progression, immune microenvironment remodeling, and therapy resistance. This study aimed to develop a mechanical stimulation-related gene (MSRG)-based prognostic signature for survival prediction and to explore its association with the tumor immune microenvironment in lung adenocarcinoma (LUAD). - Source: PubMed
Publication date: 2026/09/16
Zhang WeihaoSun YanLi JinSun TongyouLiu Lei - Hypoxia is a key driver of tumor progression across cancers, yet oxygen-sensing mechanisms beyond HIFs remain underexplored. 2-Aminoethanethiol dioxygenase (ADO) has recently been identified as an oxygen sensor, but its role in malignancy is poorly defined. We conducted a pan-cancer analysis of ADO with a special focus on hepatocellular carcinoma (HCC), to assess its oncogenic significance and clinical potential. - Source: PubMed
Publication date: 2026/09/24
Huang JieXu YingWang YuqingNie YuzhouChen YidanShen JuanMa ShenglinChen Xueqin - Epidermal growth factor receptor (EGFR), cellular mesenchymal-epithelial transition factor (c-MET), and B7 homolog 3 (B7H3) are important targets for antibody-based drug development in colorectal cancer (CRC). To overcome the limitations of single-target antibody therapies - such as limited efficacy, widespread resistance, narrow patient populations, and treatment-related toxicities - various bispecific antibodies or antibody-drug conjugate (ADCs) targeting two targets are being extensively validated in clinical settings. A deeper understanding of their expression profiles and co-expression patterns of actionable therapeutic targets may guide more effective treatment strategies. We evaluated the immunohistochemical expression of B7H3, c-MET, and EGFR in a cohort of 193 CRC patients. Among which, B7H3 exhibited the highest positivity rate (80.83%) in CRC tissues, followed by c-MET (77.20%) and EGFR (47.15%). The positive rates of B7H3 showed no significant differences across patient gender, age, TNM stage, differentiation grade, or tumor site. In contrast, the c-MET positivity rate was elevated in patients with stage I-II disease, and the expression of EGFR was significantly higher in female patients than in male patients. Concurrent assessment of the three targets in metastatic lesions revealed that B7H3 expression levels were comparable between primary and metastatic tumors, whereas c-MET expression was significantly higher in primary lesions. Co-expression analysis indicated that the group with the highest patient coverage was the B7H3/c-MET dual-positive group, followed by the B7H3/EGFR, and c-MET/EGFR combinations, and the proportion of patients with at least one positive target exceeded 80%. Finally, mRNA profile from TIMER database reveals that CD276 and MET expression in CRC tumor tissues were higher than those in the majority of normal tissues. Therefore, utilizing B7H3/c-MET combination therapies that integrate intracellular signaling inhibition with immune checkpoint modulation could potentially extend therapeutic benefits to a wider range of CRC patients. - Source: PubMed
Yang YananLi HuiyuXiao ShiweiJiao MengxiaWu DeAo ChunxiaZhang YanggelingYan SiyuanSun ShaomeiYang ChenTang RenhongWang XiyuanYue Junqiu - Chimeric antigen receptor (CAR)-T cell therapy for solid tumors is limited by antigen heterogeneity and T cell exhaustion. To address these limitations, we develop a novel multi-targeting "Bicephali" CAR-T platform featuring a dual-transmembrane protein with two distinct extracellular antigen-binding domains and a shared intracellular 4-1BB co-stimulatory/CD3ζ signaling domain. CD276 and NKG2D ligands (NKG2DLs) show high and heterogeneous expression in non-small cell lung cancer (NSCLC) and are undetectable in normal tissues. Bicephali CAR-T cells targeting CD276 and NKG2DLs demonstrate superior tumoricidal activity against NSCLC than conventional BB002 CAR-T cells in vitro and in vivo, together with improved immunological synapse formation and mitochondrial metabolic fitness. In homogeneous NSCLC models co-expressing CD276 and NKG2DLs, Bicephali CAR-T cells achieve prolonged survival outcomes compared to monospecific CAR-T cells. In antigenically heterogeneous NSCLC, Bicephali CAR-T cells more consistently control tumors and prolong survival, whereas monospecific CAR-T cells fail to eliminate tumors following antigen loss. Mechanistically, improved mitochondrial fitness and antioxidant capacity in Bicephali CAR-T cells are associated with sustained T cell function, preserved stem-like differentiation, and durable effector responses. These findings support a multi-targeting CAR-T approach to address antigen heterogeneity in NSCLC and potentially other solid tumors. - Source: PubMed
Publication date: 2026/09/27
Wang LinaZhang YanleiPeng ShuixiuHou ChenchenGuo HuaqiZhou TianyuChang Alex HYan LifengXiong Weining - Sarcomas are a heterogeneous group of mesenchymal malignancies characterized by substantial morphological and molecular diversity. Despite advances in surgery and systemic therapies, outcomes remain poor, underscoring the need for novel biomarkers and targeted therapies. We systematically assessed B7-H3 status in sarcomas. Forty-six studies were included (25 preclinical, 13 clinical, and eight mixed studies), most of which focused on osteosarcoma, rhabdomyosarcoma, and Ewing sarcoma. B7-H3 expression varied considerably across sarcoma subtypes and according to detection and scoring methods. The available evidence implicated B7-H3 in oncogenic transcriptional programs, miR-124 downregulation, matrix metalloproteinase-mediated shedding, and signaling pathways including PI3K-AKT-mTOR, MAPK, Wnt/β-catenin, and epithelial-mesenchymal transition. Emerging therapeutic strategies targeting B7-H3 included CAR T-cell therapies, antibody-drug conjugates, Fc-optimized antibodies, radiolabeled antibodies, and fluorescence-guided surgery. In clinical evidence, B7-H3 expression showed potential associations with disease progression and selected survival outcomes; however, findings were limited by heterogeneous methodologies and relatively sparse clinical data. B7-H3 represents a promising biomarker and therapeutic target in sarcomas, with substantial preclinical evidence supporting its biological and therapeutic relevance. However, standardized approaches to B7-H3 detection and scoring, together with well-designed prospective clinical studies, are needed to establish its prognostic and predictive value and determine the clinical efficacy of B7-H3-directed therapies. - Source: PubMed
Publication date: 2026/09/27
Alwisi NouranHamid Mohammad AbdelGhith DahabAlshare SalamAdham LujainSami SamihaBabu Giridhara RathnaiahVranić Semir